PH25733A - 5-aryl-3h-1,2,4-triazol-3-ones, their use in the treatment of neurogenerative disorders - Google Patents

5-aryl-3h-1,2,4-triazol-3-ones, their use in the treatment of neurogenerative disorders

Info

Publication number
PH25733A
PH25733A PH36230A PH36230A PH25733A PH 25733 A PH25733 A PH 25733A PH 36230 A PH36230 A PH 36230A PH 36230 A PH36230 A PH 36230A PH 25733 A PH25733 A PH 25733A
Authority
PH
Philippines
Prior art keywords
triazol
aryl
ones
treatment
neurogenerative disorders
Prior art date
Application number
PH36230A
Inventor
Francis P Miller
Stephen Sorensen
John M Kane
Original Assignee
Merrel Dow Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrel Dow Pharmaceuticals filed Critical Merrel Dow Pharmaceuticals
Publication of PH25733A publication Critical patent/PH25733A/en

Links

PH36230A 1987-10-16 1987-12-15 5-aryl-3h-1,2,4-triazol-3-ones, their use in the treatment of neurogenerative disorders PH25733A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10700187A 1987-10-16 1987-10-16

Publications (1)

Publication Number Publication Date
PH25733A true PH25733A (en) 1991-10-18

Family

ID=22314340

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36230A PH25733A (en) 1987-10-16 1987-12-15 5-aryl-3h-1,2,4-triazol-3-ones, their use in the treatment of neurogenerative disorders

Country Status (2)

Country Link
PH (1) PH25733A (en)
ZA (1) ZA879420B (en)

Also Published As

Publication number Publication date
ZA879420B (en) 1988-07-27

Similar Documents

Publication Publication Date Title
GB2207055B (en) Apparatus for use in the treatment of spinal disorders
EP0205579A4 (en) Methods and compositions useful in the diagnosis and treatment of autoimmune diseases.
EP0275668A3 (en) Use of ketone derivatives in the treatment of cognitive disorders
AU624067B2 (en) Preparation suitable for use in the treatment of enteric disorders
ZA913497B (en) Azabenzimidazoles in the treatment of asthma,arthritis and related diseases
EP0437026A3 (en) Use of tandospirone in the treatment of depression
GB2177398B (en) 5,6-epoxy-7-oxabicycloheptane substituted ethers useful in the treatment of thrombotic disease
GB2203645B (en) Improvements in the treatment of hair
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
EP0427427A3 (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
EP0271127A3 (en) Use of guaifenesin in the treatment of urologic disorders
ZA887364B (en) Ovulation treatment
PH25733A (en) 5-aryl-3h-1,2,4-triazol-3-ones, their use in the treatment of neurogenerative disorders
ZA87873B (en) Substituted diazapines and derivatives thereof useful in the treatment of cardiovascular disorders
JPS6422876A (en) 8 alpha-acylaminoergoline, manufacture and medicine
EP0407016A3 (en) Use of benzodioxinopyrrole derivatives in the treatment of anxiety
JPS6466148A (en) Manufacture of 1,5-diaminoheptanol-6, manufacture and use
ZA883253B (en) Improvements in the treatment of sand
SG4695G (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney-diseases
EP0269024A3 (en) Use of 3-methyl-4-oxothiazolidin-2-ylidene-acetamide derivatives in the treatment of aids
GB8724439D0 (en) Treatment
GB8719190D0 (en) Treatment
GB8711457D0 (en) Treatment
GB8712239D0 (en) Treatment
GB8712243D0 (en) Treatment